Skip to main content
. Author manuscript; available in PMC: 2013 Feb 11.
Published in final edited form as: Antiviral Res. 2010 May 7;87(2):195–203. doi: 10.1016/j.antiviral.2010.04.013

Figure 3.

Figure 3

Survival of CD-1 mice treated by subcutaneous CLDC administration at the inner thigh 24h prior to infection, at the same time as infection (0h), or 24h post infection with WEEV-McMillan delivered by subcutaneous injection at the inner thigh.